| What it is | Patients with confirmed pleomorphic liposarcoma receive pembrolizumab administered every 6 weeks by intravenous infusion (up to 8 doses). | This group includes adults with perivascular epithelioid cell tumor (PEComa) treated with pembrolizumab infusions on the same schedule. | Adults with epithelioid sarcoma in this arm also receive pembrolizumab by intravenous infusion every 6 weeks as directed by the study. | Patients confirmed to have CIC-rearranged sarcoma receive pembrolizumab infusions administered every 6 weeks, according to study protocol. | This cohort includes patients with sclerosing epithelioid fibrosarcoma or low-grade fibromyxoid sarcoma who are given pembrolizumab infusions on the same regimen. |
|---|
| Primary use | Study treatment for adults with pleomorphic liposarcoma whose disease has recurred or metastasized and is not curable by other means. | Study treatment for adults with PEComa with recurrent or metastatic tumors not curable with current options. | Study-provided pembrolizumab for adults with unresectable, recurrent, or metastatic epithelioid sarcoma after prior therapies. | Investigation of pembrolizumab as therapy for recurrent or metastatic CIC-rearranged sarcoma in adults. | Designed for adults with sclerosing epithelioid fibrosarcoma or low-grade fibromyxoid sarcoma that has returned or spread, to evaluate pembrolizumab. |
|---|
| How it is given or performed | Pembrolizumab is administered through an intravenous infusion once every 6 weeks, for up to 8 doses, unless disease progression or unacceptable side effects occur first. | Participants receive pembrolizumab as an intravenous infusion every 6 weeks, with a maximum of 8 doses, adjusted for toxicity or response. | Pembrolizumab is given by slow intravenous infusion on the first day of each 6-week cycle, repeated up to eight times or until the treatment is stopped. | The drug is infused intravenously on Day 1 of every 6-week cycle, up to 8 cycles, with earlier discontinuation if clinically indicated. | Pembrolizumab infusions occur once every 6 weeks, up to a maximum of 8 doses or until disease progression or intolerable side effects. |
|---|
| Evidence status | There are no published study results yet; pembrolizumab’s effectiveness for pleomorphic liposarcoma in this setting is still under clinical investigation. | The effect of pembrolizumab on PEComa remains unproven; no results have been posted for this population but data will be collected prospectively. | Pembrolizumab’s effects in epithelioid sarcoma are still being studied; clinical benefit and risks are unknown pending trial completion and analysis. | There is no published efficacy data for pembrolizumab in CIC-rearranged sarcoma; evidence will depend on trial outcomes. | Evidence for pembrolizumab in sclerosing epithelioid fibrosarcoma or low-grade fibromyxoid sarcoma is not yet available; results are awaited from this study. |
|---|
| Important limitations | The size of the study cohort is small and there is no control or standard-care group, which may limit the ability to draw definitive conclusions about pembrolizumab's effectiveness or safety for pleomorphic liposarcoma. | As with other arms, the lack of a comparator group and the rarity of PEComa mean results may be difficult to interpret, and any findings will require further validation. | Small patient numbers and the absence of a standard-of-care comparator limit the strength of the evidence provided by this arm. | Results for CIC-rearranged sarcoma may have limited generalizability due to small participant count and lack of a control group. | Very limited cohort size, absence of comparator group, and ultra-rare disease context may limit interpretation of any observed benefit or risks. |
|---|
